Table 1

Demographic and baseline values before to initial treatment assignment

Age (years)58.1 ± 9.2
Women14 (58.3)
Men10 (41.7)
Diabetes medication use*20 (83.3)
Lipid-lowering medication use†13 (54.2)
Blood pressure–lowering medication use‡17 (70.8)
Baseline diameter (mm)4.2 ± 0.8
Absolute change in diameter (mm)0.3 ± 0.1
FMD (%)8.6 ± 4.3
Stimulus-adjusted response measure0.08 ± 0.05
BMI (kg/m2)32.5 ± 5.0
Weight (kg)89.0 ± 15.5
Waist circumference (cm)103.1 ± 11.3
Systolic blood pressure (mmHg)133.2 ± 14.0
Diastolic blood pressure (mmHg)77.7 ± 7.3
Mean blood pressure (mmHg)105.4 ± 9.9
Fasting serum glucose (mg/dl)129.7 ± 34.4
Serum insulin (mIU/ml)15.6 ± 12.4
Insulin resistance2.1 ± 1.5
Plasma A1C (%)6.7 ± 0.9
Serum total cholesterol (mg/dl)183.4 ± 38.9
Serum triglycerides (mg/dl)123.6 ± 67.0
Serum HDL cholesterol (mg/dl)56.0 ± 14.7
Serum LDL cholesterol (mg/dl)102.9 ± 32.4
Serum cholesterol–to-HDL cholesterol ratio3.4 ± 1.0
  • Data are means ± SD or n (%). n = 24.

  • *Included metformin (n = 18), glipizide (n = 3), chlorpropamide (n = 1), sitagliptin (n = 3), pioglitazone (n = 5), and glyburide (n = 3).

  • †Included atorvastatin (n = 5), pravastatin (n = 2), simvastatin (n = 2), fenofibrate (n = 1), lovastatin (n = 1), rosuvastatin (n = 1), and ezetimibe/simvastatin (n = 1).

  • ‡Included lisinopril (n = 9), verapamil (n = 1), irbesartan (n = 1), atenolol (n = 1), metoprolol (n = 2), valsartan (n = 1), enalapril (n = 1), hydrochlorothiazide/moexipril (n = 1), nadolol (n = 1), and olmesartan (n = 1).